2
|
Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer. Breast Cancer Res Treat 2016; 160:457-474. [PMID: 27771839 PMCID: PMC10183099 DOI: 10.1007/s10549-016-4011-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Accepted: 10/05/2016] [Indexed: 01/25/2023]
Abstract
PURPOSE Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in human breast cancer. Furthermore, PIK3CA mutations are commonly associated with resistance to anti-epidermal growth factor receptor 2 (HER2) or anti-estrogen receptor (ER) agents in HER2 or ER positive (HER2+/ER+) breast cancer. Hence, deciphering the underlying mechanisms of PIK3CA mutations in HER2+/ER+ breast cancer would provide novel insights into elucidating resistance to anti-HER2/ER therapies. METHODS In this study, we systematically investigated the biological consequences of PIK3CA H1047R in HER2+/ER+ breast cancer by uniquely incorporating mRNA transcriptomic data from The Cancer Genome Atlas and proteomic data from reverse-phase protein arrays. RESULTS Our integrative bioinformatics analyses revealed that several important pathways such as STAT3 and VEGF/hypoxia were selectively altered by PIK3CA H1047R in HER2+/ER+ breast cancer. Protein differential expression analysis indicated that an elevated eIF4G might promote tumor angiogenesis and growth via regulation of the hypoxia-activated switch in HER2+ PIK3CA H1047R breast cancer. We observed hypo-phosphorylation of EGFR in HER2+ PIK3CA H1047R breast cancer versus HER2+PIK3CAwild-type (PIK3CA WT). In addition, ER and PIK3CA H1047R might cooperate to activate STAT3, MAPK, AKT, and Hippo pathways in ER+ PIK3CA H1047R breast cancer. A higher YAPpS127 level was observed in ER+ PIK3CA H1047R patients than that in an ER+ PIK3CA WT subgroup. By examining breast cancer cell lines having both microarray gene expression and drug treatment data from the Genomics of Drug Sensitivity in Cancer and the Stand Up to Cancer datasets, we found that the elevated YAP1 mRNA expression was associated with the resistance of BCL-2 family inhibitors, but with the sensitivity to MEK/MAPK inhibitors in breast cancer cells. CONCLUSIONS In summary, these findings shed light on the functional consequences of PIK3CA H1047R-driven breast tumorigenesis and resistance to the existing therapeutic agents in HER2+/ER+ breast cancer.
Collapse
Affiliation(s)
- Feixiong Cheng
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, 37203, USA.,Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.,Center for Complex Networks Research, Northeastern University, Boston, MA, 02115, USA
| | - Junfei Zhao
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, 37203, USA.,Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA
| | - Ariella B Hanker
- Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Monica Red Brewer
- Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Carlos L Arteaga
- Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
| | - Zhongming Zhao
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, 37203, USA. .,Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. .,Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. .,Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
| |
Collapse
|
5
|
von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S. German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer. J Clin Oncol 2013; 31:3531-9. [DOI: 10.1200/jco.2012.47.2167] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Bisphosphonates prevent skeletal-related events in patients with metastatic breast cancer. Their effect in early breast cancer is controversial. Ibandronate is an orally and intravenously available amino-bisphosphonate with a favorable toxicity profile. It therefore qualifies as potential agent for adjuvant use. Patients and Methods The GAIN (German Adjuvant Intergroup Node-Positive) study was an open-label, randomized, controlled phase III trial with a 2 × 2 factorial design. Patients with node-positive early breast cancer were randomly assigned 1:1 to two different dose-dense chemotherapy regimens and 2:1 to ibandronate 50 mg per day orally for 2 years or observation. In all, 2,640 patients and 728 events were estimated to be required to demonstrate an increase in disease-free survival (DFS) by ibandronate from 75% to 79.5% by using a two-sided α = .05 and 1-β of 80%. We report here the efficacy analysis for ibandronate, which was released by the independent data monitoring committee because the futility boundary was not crossed after 50% of the required DFS events were observed. Results Between June 2004 and August 2008, 2,015 patients were randomly assigned to ibandronate and 1,008 to observation. Patients randomly assigned to ibandronate showed no superior DFS or overall survival (OS) compared with patients randomly assigned to observation (DFS: hazard ratio, 0.945; 95% CI, 0.768 to 1.161; P = .589; OS: HR, 1.040; 95% CI, 0.763 to 1.419; P = .803). DFS was numerically longer if ibandronate was used in patients younger than 40 years or older than 60 years compared with patients age 40 to 59 years (test for interaction P = .093). Conclusion Adjuvant treatment with oral ibandronate did not improve outcome of patients with high-risk early breast cancer who received dose-dense chemotherapy.
Collapse
Affiliation(s)
- Gunter von Minckwitz
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Volker Möbus
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Andreas Schneeweiss
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Jens Huober
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Christoph Thomssen
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Michael Untch
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Christian Jackisch
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Ingo J. Diel
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Dirk Elling
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Bettina Conrad
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Rolf Kreienberg
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Volkmar Müller
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Hans-Joachim Lück
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Ingo Bauerfeind
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Michael Clemens
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Marcus Schmidt
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Stefanie Noeding
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Helmut Forstbauer
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Jana Barinoff
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Antje Belau
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Valentina Nekljudova
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Nadia Harbeck
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| | - Sibylle Loibl
- Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für
| |
Collapse
|